Sugi Predict

Sugi Predict / Compounds / SCHEMBL707335

SCHEMBL707335

SCHEMBL707335

CC(C)Cc1cc(B(O)O)c(S(=O)(=O)NC(C)(C)C)s1

nearest known ligand 0.34

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ AGTR2 P50052 8/20 0.34
▸ LMNA P02545 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ PARG Q86W56 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29955315 0.82 ALDH1A1 (0.33) LMNASMN1; SMN2ALDH1A1PARGKDM4E
SCHEMBL9128667 0.82 AGTR2 (0.34) AGTR2CYP3A4
SCHEMBL30308708 0.81 AGTR2 (0.33) AGTR2LMNASMN1; SMN2ALDH1A1CYP3A4
SCHEMBL710923 0.80 AGTR2 (0.32) AGTR2LMNASMN1; SMN2ALDH1A1KDM4E
SCHEMBL710338 0.75 AGTR2 (0.51) AGTR2
SCHEMBL26126025 0.72 — —
SCHEMBL4181608 0.72 AGTR2 (0.46) AGTR2
SCHEMBL707086 0.72 AGTR2 (0.48) AGTR2
SCHEMBL710753 0.71 ALDH1A1 (0.35) LMNAALDH1A1KDM4EMEN1NPC1
SCHEMBL29107879 0.71 ALDH1A1 (0.39) LMNASMN1; SMN2ALDH1A1PARGKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028333-A1 NEW COMPOUNDS VICORE PHARMA AB (SE) 2026-01-29 — — US disclosed
US-12435072-B2 Compounds VICORE PHARMA AB (SE) 2025-10-07 — — US disclosed
US-20250214978-A1 AT2R AGONIST Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2025-07-03 — — US disclosed
WO-2025044927-A1 THIOPHENE SULFONYL CARBAMATE AS AT2R AGONIST, AND USE THEREOF 武汉人福创新药物研发中心有限公司 2025-03-06 — — WO disclosed
CN-119504722-A Thiophene sulfonyl carbamate serving as AT2R agonist and application thereof 武汉人福创新药物研发中心有限公司 2025-02-25 — — CN disclosed
EP-4506345-A1 AT2R AGONIST Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2025-02-12 — — EP disclosed
EP-4121047-B1 IMIDAZOLYL THIOPHENE SULFONYL CARBAMATES FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II VICORE PHARMA AB (SE) 2024-10-30 — — EP disclosed
US-20240174657-A1 SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS VICORE PHARMA AB (SE) 2024-05-30 — — US disclosed
EP-4313976-A1 SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS Vicore Pharma AB (SE) 2024-02-07 — — EP disclosed
CN-117263922-A Heterocyclic compounds as AT2R agonists 武汉人福创新药物研发中心有限公司 2023-12-22 — — CN disclosed
EP-1869024-B1 NEW TRICYCLIC ANGIOTENSIN II AGONISTS VICORE PHARMA AB (SE) 2010-11-10 — — EP disclosed
US-7652054-B2 Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB (SE) 2010-01-26 — — US disclosed
US-20090326026-A1 Tricyclic Compounds Useful as Angiotensin II Agonists VICORE PHARMA AB 2009-12-31 — — US disclosed
US-20090215847-A1 Tricyclic Angiotensin II Agonists VICORE PHARMA AB (SE) 2009-08-27 — — US disclosed
US-20090069382-A1 Bicyclic Angiotensin II Agonists VICORE PHARMA AB (SE) 2009-03-12 — — US disclosed
US-20090042931-A1 Tricyclic Angiotensin II Agonists VICORE PHARMA AB (SE) 2009-02-12 — — US disclosed
EP-1869009-A1 NEW BICYCLIC ANGIOTENSIN II AGONISTS Vicore Pharma AB (SE) 2007-12-26 — — EP disclosed
EP-1395566-B1 TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS VICORE PHARMA AB (SE) 2007-09-12 — — EP disclosed
WO-2006109058-A1 NEW BICYCLIC ANGIOTENSIN II AGONISTS VICORE PHARMA AB (SE) 2006-10-19 — — WO disclosed
US-20040167176-A1 Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB (SE) 2004-08-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028333-A1 NEW COMPOUNDS AGTR1, AGTR2, REN AGTR2 2/4885LMNA 1958/4885SMN1; SMN2 4062/4885
US-20040167176-A1 Tricyclic compounds useful as angiotensin II agonists AGTR1, AGTR2, NPY2R AGTR2 2/4885LMNA 4221/4885SMN1; SMN2 4394/4885
US-20090326026-A1 Tricyclic Compounds Useful as Angiotensin II Agonists AGTR2, AGTR1, NPY4R AGTR2 1/4885LMNA 4215/4885SMN1; SMN2 4272/4885
US-20090069382-A1 Bicyclic Angiotensin II Agonists AGTR2, AGTR1, BDKRB2 AGTR2 1/4885LMNA 4087/4885SMN1; SMN2 3782/4885
US-20250214978-A1 AT2R AGONIST AGTR1, AGTR2, AVPR2 AGTR2 2/4885LMNA 3576/4885SMN1; SMN2 3701/4885
US-20090042931-A1 Tricyclic Angiotensin II Agonists AGTR2, AGTR1, NPY4R AGTR2 1/4885LMNA 4197/4885SMN1; SMN2 3738/4885
US-20240174657-A1 SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS AGTR1, AGTR2, MSR1 AGTR2 2/4885LMNA 3605/4885SMN1; SMN2 4375/4885
US-12435072-B2 Compounds RXFP3, RXFP4, ARG1 AGTR2 94/4885LMNA 2591/4885SMN1; SMN2 3930/4885
US-20090215847-A1 Tricyclic Angiotensin II Agonists AGTR2, AGTR1, NPY2R AGTR2 1/4885LMNA 3768/4885SMN1; SMN2 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.